Skandinaviska Enskilda Banken AB publ Increases Stake in Stryker Co. (NYSE:SYK)

Skandinaviska Enskilda Banken AB publ raised its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 61.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 165,820 shares of the medical technology company's stock after acquiring an additional 63,297 shares during the quarter. Skandinaviska Enskilda Banken AB publ's holdings in Stryker were worth $60,070,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of SYK. State Street Corp increased its position in Stryker by 2.2% in the third quarter. State Street Corp now owns 14,582,959 shares of the medical technology company's stock worth $5,279,788,000 after buying an additional 316,404 shares in the last quarter. FMR LLC increased its holdings in Stryker by 3.0% in the 3rd quarter. FMR LLC now owns 7,306,994 shares of the medical technology company's stock worth $2,639,725,000 after acquiring an additional 215,782 shares in the last quarter. Geode Capital Management LLC raised its stake in Stryker by 2.5% during the 3rd quarter. Geode Capital Management LLC now owns 6,905,126 shares of the medical technology company's stock worth $2,484,893,000 after acquiring an additional 165,490 shares during the period. Parnassus Investments LLC bought a new position in shares of Stryker in the third quarter worth approximately $762,798,000. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Stryker by 2.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,985,045 shares of the medical technology company's stock worth $714,715,000 after purchasing an additional 48,819 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Insiders Place Their Bets

In other news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company's stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Stryker Trading Down 0.5 %

Shares of SYK opened at $363.52 on Thursday. The company has a 50-day moving average of $382.76 and a 200 day moving average of $373.33. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The firm has a market capitalization of $138.71 billion, a price-to-earnings ratio of 46.85, a PEG ratio of 2.93 and a beta of 0.95.

Remove Ads

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the company earned $3.46 earnings per share. On average, research analysts expect that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date is Monday, March 31st. Stryker's payout ratio is currently 43.30%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on SYK. The Goldman Sachs Group set a $422.00 target price on shares of Stryker in a research note on Tuesday, March 4th. Needham & Company LLC restated a "buy" rating and issued a $442.00 price objective on shares of Stryker in a research report on Wednesday, January 29th. JMP Securities reiterated a "market perform" rating on shares of Stryker in a research report on Tuesday, February 18th. Stifel Nicolaus boosted their price target on Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a report on Wednesday, January 29th. Finally, Wells Fargo & Company increased their price objective on shares of Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $421.90.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.